Cathepsin S: Therapeutic, diagnostic, and prognostic potential

Biological Chemistry

Volumn 396, Issue 8, 2015, Pages 867-882

  Wilkinson, Richard D A ^a   Williams, Rich ^a   Scott, Christopher J ^a   Burden, Roberta E ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

biomarker; inhibitor; probes; substrates

Indexed keywords

CARBOXYPEPTIDASE C; CATHEPSIN B; CATHEPSIN D; CATHEPSIN E; CATHEPSIN F; CATHEPSIN G; CATHEPSIN H; CATHEPSIN K; CATHEPSIN L; CATHEPSIN O; CATHEPSIN S; CATHEPSIN V; CATHEPSIN W; CATHEPSIN X; DIPEPTIDYL PEPTIDASE I; UNCLASSIFIED DRUG; CATHEPSIN;

ARTHRITIS; ASTHMA; BREAST CANCER; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; CYSTIC FIBROSIS; DIABETES MELLITUS; HUMAN; INFLAMMATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; NONHUMAN; OBESITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; CARDIOVASCULAR DISEASES; METABOLISM; NEOPLASMS; PATHOLOGY; PH;

ANIMALS; ARTHRITIS; CARDIOVASCULAR DISEASES; CATHEPSINS; HUMANS; HYDROGEN-ION CONCENTRATION; NEOPLASMS; PROGNOSIS;

EID: 84936805469     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2015-0114     Document Type: Review

References (138)

1. Baugh, M., Black, D., Westwood, P., Kinghorn, E., McGregor, K., Bruin, J., Hamilton, W., Dempster, M., Claxton, C., Cai, J., et al. (2011). Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J. Autoimmun. 36, 201-209.
2. Beck, H., Schwarz, G., Schröter, C.J., Deeg, M., Baier, D., Stevanovic, S., Weber, E., Driessen, C., and Kalbacher, H. (2001). Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Immunology 31, 3726-3736.
3. Berger, A.B., Vitorino, P.M., and Bogyo, M. (2004). Activity-based protein profiling: applications to biomarker discovery, in vivo imaging and drug discovery. Am. J. Pharmacogenomics 4, 371-381.
4. Beroukhim, R., Mermel, C.H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J.S., Dobson, J., Urashima, M., et al. (2010). The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905.
5. Black, W.C. and Percival, M.D. (2006). The consequences of lysosomotropism on the design of selective cathepsin K inhibitors. Chembiochem 7, 1525-1635.
6. Blum, G., Mullins, S.R., Keren, K., Fonovic, M., Jedeszko, C., Rice, M.J., Sloane, B.F., and Bogyo, M. (2005). Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat. Chem. Biol. 1, 203-209.
7. Blum, G., von Degenfeld, G., Merchant, M.J., Blau, H.M., and Bogyo, M. (2007). Non-invasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat. Chem. Biol. 3, 668-677.
8. Blum, G., Weimer, R.M., Edgington, L.E., Adams, W., and Bogyo, M. (2009). Comparative assessment of substrates and activity based probes as tools for non-invasive optical imaging of cysteine protease activity. PLoS One 4, e6374.
9. Bremer, C., Tung, C-H., Bogdanov, A., and Weissleder, R. (2002). Imaging of differential protease expression in breast cancers fordetection of aggressive tumor phenotypes. Radiology 222, 814-818.
10. Brix, K., Scott, C.J., Heck, M.M.S. (2013). Compartmentalization of Proteolysis. In: Protease: Structure and Function. K. Brix and W. Stöcker, eds. (Springer-Verlag Wien 2013), pp. 85-126.
11. Burden, R.E., Gormley, J.A., Jaquin, T.J., Small, D.M., Quinn, D.J., Hegarty, S.M., Ward, C., Walker, B., Johnston, J.A., Olwill, S.A., et al. (2009). Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin. Cancer. Res. 15, 6042-6051.
12. Burden, R.E., Gormley, J.A., Kuehn, D., Ward, C., Kwok, H.F., Gazdoiu, M., McClurg, A., Jaquin, T.J., Johnston, J.A., Scott, C.J., et al. (2012). Inhibition of cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. Biochemie 94, 487-493.
13. Caglič, D., Globisch, A., Kindermann, M., Lim, N-H., Jeske, V., Juretschke, H-P., Bartnik, E., Weithmann, K.U., Nagase, H., Turk, B., et al. (2011). Functional in vivo imaging of cysteine cathepsin activity in murine model of inflammation. Bioorg. Med. Chem. 19, 1055-1061.
14. Capelozzi, V.L. (2009). Role of immunohistochemistry in the diagnosis of lung cancer. J. Bras. Pneumol. 35, 375-382.
15. Cattaruzza, F., Lyo, V., Jones, E., Pham, D., Hawkins, J., Kirkwood, K., Valdez-Morales, E., Ibeakanma, C., Vanner, S.J., Bogyo, M., et al. (2011). Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice. Gastroenterology 141, 1864-1874.
16. Chang, W-S.W., Wu, H-R., Yeh, C-T., Wu, C-W., and Chang, J-Y. (2007). Lysosomal cysteine proteinase cathepsin S as a potential target for anti-cancer therapy. J. Cancer Mol. 1, 5-14.
17. Chapman, H.A., Riese, R.J., and Shi, G.P. (1997). Emerging roles for cysteine proteases in human biology. Annu. Rev. Physiol. 59, 63-88.
18. Chen, R-P., Ren, A., and Ye, S-D. (2013a). Correlation between serum cathepsin S and insulin resistance in type 2 diabetes. Exp. Ther. Med. 6, 1237-1242.
19. Chen, H., Wang, J., Xiang, M-X., Lin, Y., He, A., Jin, C-N., Guan, J., Sukhova, G.K., Libby, P., Wang, J-A., et al. (2013b). Cathepsin S-mediated fibroblast trans-differentiation contributes to left ventricular remodelling after myocardial infarction. Cardiovasc. Res. 100, 84-94.
20. Cimerman, N., Brguljan, P.M., Krasovec, M., Suskovic, S., and Kos, J. (2001). Circadian and concentration profile of cathepsin S in sera from healthy subjects and asthmatic patients. Pflüger's Arch. 442, R204-R206.
21. Clark, A.K., Yip, P.K., Grist, J., Gentry, C., Staniland, A.A., Marchand, F., Dehvari, M., Wotherspoon, G., Winter, J., Ullah, J., et al. (2007). Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc. Natl. Acad. Sci. USA 104, 10655-10660.
22. Clark, A.K., Yip, P.K., and Malcangio, M. (2009). The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J. Neurosci. 29, 6945-6954.
23. Conus, S. and Simon, H-U. (2010). Cathepsins and their involvement in immune responses. Swiss. Med. Wkly. 140, w13042.
24. Cortez-Retamozo, V., Swirski, F.K., Waterman, P., Yuan, H., Figueiredo, J.L., Newton, A.P., Upadhyay, R., Vinegoni, C., Kohler, R., Blois, J., et al. (2008). Real-time assessment of inflammation and treatment response in a mouse model of allergic airway inflammation. J. Clin. Invest. 118, 4058-4066.
25. Cox, J.M., Troutt, J.S., Knierman, M.D., Siegel, R.W., Qian, Y-W., Ackermann, B.L., and Konrad, R.J. (2012). Determination of cathepsin S abundance and activity in human plasma and implications for clinical investigation. Anal. Biochem. 430, 130-137.
26. Deschamps, K., Cromlish, W., Weicker, S., Lamontagne, S., Huzsar, S.L., Gauthier, J.Y., Mudgett, J.S., Guimond, A., Romand, R., Frossard, N., et al. (2011). Genetic and pharmacological evaluation of cathepsin S in a mouse model of asthma. Am. J. Respir. Cell. Mol. Biol. 45, 81-87.
27. Dickinson, D.P. (2002). Cysteine peptidases of mammals: their biological roles and potential effects in the oral cavity and other tissues in health and disease. Crit. Rev. Oral. Biol. Med. 13, 238-275.
28. Drenth, J., Jansonius, J.N., Koekoek, R., Swen, H.M., and Wolthers, B.G. (1968). Structure of papain. Nature 218, 929-932.
29. Edgington, L.E., Verdoes, M., and Bogyo, M. (2011). Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes. Curr. Opin. Chem. Biol. 15, 798-805.
30. Elmariah, S.B., Reddy, V.B., and Lerner, E.A. (2014). Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist. PLoS One 9, e99702.
31. Fajardo, I., Svensson, L., Bucht, A., and Pejler, G. (2004). Increased levels of hypoxia-sensitive proteins in allergic airway inflamtion. Am. J. Respir. Crit. Care. Med. 170, 477-484.
32. Falgueyret, J-P., Desmarais, S., Oballa, R., Black, W.C., Cromlish, W., and Khougaz, K. (2005). Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J. Med. Chem. 48, 7535-7543.
33. Fay, F. and Scott, C.J. (2011). Antibody-targeted nanoparticles for cancer therapy. Immunotherapy 3, 381-394.
34. Fernández, P.L., Farré, X., Nadal, A., Fernández, E., Peiró, N., Sloane, B.F., Shi, G-P., Chapman, H.A., Campo, E., and Cardesa, A. (2001). Expression of cathepsins B and S in the progression of prostate carcinoma. Int. J. Cancer 55, 51-55.
35. Firestein, G.S. (2005). Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 11, S39-S44.
36. Flannery, T., McQuaid, S., McGoohan, C., McConnell, R.S., McGregor, G., Mirakhur, M., Hamilton, P., Diamond, J., Cran, G., Walker, B., et al. (2006). Cathepsin S expression: an independent prognostic factor in glioblastoma tumours - a pilot study. Int. J. Cancer 119, 854-860.
37. Gangadharan, V. and Kuner, R. (2013). Pain hypersensitivity mechanisms at a glance. Dis. Model. Mech. 6, 889-895.
38. Gauthier, J.Y., Chauret, N., Cromlish, W., Desmarais, S., Duong, L.T., Falgueyret, J., Kimmel, D.B., Lamontagne, S., Léger, S., Le Riche, T., et al. (2008). The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg. Med. Chem. Lett. 18, 923-928.
39. Gocheva, V., Zeng, W., Ke, D., Klimstra, D., Reinheckel, T., Peters, C., Hanahan, D., and Joyce, J. A. (2006). Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes. Dev. 20, 543-556.
40. Gocheva, V., Wang, H-W., Gadea, B.B., Shree, T., Hunter, K.E., Garfall, A.L., Berman, T., and Joyce, J.A. (2010). IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes. Dev. 24, 241-255.
41. Gormley, J.A., Hegarty, S.M., O'Grady, A., Stevenson, M.R., Burden, R.E., Barrett, H.L., Scott, C.J., Johnston, J.A., Wilson, R.H., Kay, E.W., et al. (2011). The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study. Br. J. Cancer 105, 1487-1494.
42. Gounaris, E., Tung, C.H., Restaino, C., Maehr, R., Kohler, R., Joyce, J.A., Plough, H.L., Barrett, T.A., Weissleder, R., and Khazaie, K. (2008). Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS One 3, e2916.
43. Grimm, J., Kirsch, D.G., Windsor, S.D., Kim, C.F.B., Santiago, P.M., Ntziachristos, V., Jacks, T., and Weissleder, R. (2005). Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc. Natl. Acad. Sci. USA 102, 14404-14409.
44. Haerteis, S., Krappitz, M., Bertog, M., Krappitz, A., Baraznenok, V., Henderson, I., Lindström, E., Murphy, J.E., Bunnett, N.W., and Korbmacher, C. (2012). Proteolytic activation of the epithelial sodium channel (ENaC) by the cysteine protease cathepsin-S. Pflüger's Arch. 464, 353-365.
45. Hamm-Alvarez, S.F., Janga, S.R., Edman, M.C., Madrigal, S., Shah, M., Frousiakis, S.E., Renduchintala, K., Zhu, J., Bricel, S., Silka, K., et al. (2014). Tear cathepsin S as a candidate biomarker for Sjögren's syndrome. Arthritis Rheumatol. 66, 1872-1881.
46. Hanahan, D. and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
47. Haves-Zburof, D., Paperna, T., Gour-Lavie, A., Mandel, I., Glass-Marmor, L., and Miller, A. (2011). Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis. J. Cell. Mol. Med. 15, 2421-2429.
48. Hentschel, J., Fischer, N., Janhsen, W.K., Markert, U.R., Lehmann, T., Sonnemann, J., Böer, K., Pfister, W., Hipler, U., and Mainz, J.G. (2014). Protease-antiprotease imbalances differ between Cystic Fibrosis patients' upper and lower airway secretions. J. Cyst. Fibros. In Press.
49. Hervé-Grépinet, V., Veillard, F., Godat, E., Heuzé-Vourc'h, N., Lecaille, F., and Lalmanach, G. (2008). Extracellular catalase activity protects cysteine cathepsins from inactivation by hydrogen peroxide. FEBS Lett. 582, 1307-1312.
50. Honey, K. and Rudensky, A.Y. (2003). Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 3, 472-482.
51. Hsing, L.C., Kirk, E.A., Mcmillen, T.S., Hsiao, S., Houston, B., Rudensky, A.Y., and Leboeuf, R.C. (2010). Roles for cathepsins S, L, and B in insulitis and diabetes in the NOD mouse. J. Autoimmun. 34, 1-18.
52. Hu, H.Y., Vats, D., Vizovisek, M., Kramer, L., Germanier, C., Wendt, K.U., Rudin, M., Turk, B., Plettenburg, O., and Schultz, C. (2014). In vivo imaging of mouse tumours by a lipidated cathepsin S substrate. Angew. Chem. Int. Ed. Engl. 53, 7669-7673.
53. Jedinak, A. and Maliar, T. (2004). Inhibitors of proteases as anticancer drugs. Neoplasma 52, 185-192.
54. Jobs, E., Risérus, U., Ingelsson, E., Sundström, J., Jobs, M., Nerpin, E., Iggman, D., Basu, S., Larsson, A., Lind, L.A., et al. (2013). Serum cathepsin S is associated with decreased insulin sensitivity and the development of type 2 diabetes in a communitybased cohort of elderly men. Diab. Care 36, 163-165.
55. Jobs, E., Adamsson, V., Larsson, A., Jobs, M., Nerpin, E., Ingelsson, E., Arnlov, J., and Riserus, U. (2014). Influence of a prudent diet on circulating cathepsin S in humans. Nutr. J. 13, 84.
56. Jordans, S., Jenko-Kokalj, S., Kuhl, N.M., Tedelind, S., Sendt, W., Bromme, D. Turk, D., and Brix, K. (2009). Monitoring compartment-specific substrate cleavage by cathepsins B, K, L and S at physiological pH and redox conditions. BMC Biochem. 10, 23.
57. Klein, T. and Bischoff, R. (2011). Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41, 271-290.
58. Kominami, E., Ueno, T., Muno, D., and Katunuma, N. (1991). The selective role of cathepsins B and D in the lysosomal degradation of endogenous and exogenous proteins. FEBS Lett. 287, 189-192.
59. Korolenko, T.A., Poteryaeva, O.N., Falameeva, O.V., and Levina, O.A. (2003). Cysteine proteinase inhibitor stefin A as an indicator of efficiency of tumor treatment in mice. Bull. Exp. Biol. Med. 136, 46-48.
60. Kothapalli, R., Bailey, R.D., Kusmartseva, I., Mane, S., Epling-Burnette, P.K., and Loughran, T.P. (2003). Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. Int. J. Oncol. 22, 33-39.
61. Lafarge, J., Pini, M., Pelloux, V., Orasanu, G., Hartmann, G., Venteclef, N., Sulpice, T., Shi, G-P., Clément, K., and Guerre-Millo, M. (2014). Cathepsin S inhibition lowers blood glucose levels in mice. Diabetologia 57, 1674-1683.
62. Lecaille, F., Kaleta, J., and Brömme, D. (2002). Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. 102, 4459-4488.
63. Lecaille, F., Naudin, C., Sage, J., Joulin-Giet, A., Courty, A., Andrault, P., Veldhuizen, R.A.W., Possmayer, F. and Lalmanach, G. (2013). Specific cleavage of the lung surfactant protein A by human cathepsin S may impair its antibacterial properties. Int. J. Biochem. Cell. Biol. 45, 1701-1709.
64. Lee-Dutra, A., Wiener, D.K., and Sun, S (2011). Cathepsin S inhibitors: 2004-2010. Expert Opin. Ther. Pat. 21, 311-327.
65. Lewis, C.C., Yang, J.Y.H., Huang, X., Banerjee, S.K., Blackburn, M.R., Baluk, P., McDonald, D.M., Blackwell, T.S., Nagabhushanam, V., Peters, W., et al. (2007). Disease-specifica gene expression profiling in multiple models of lung disease. Am. J. Respir. Crit. Care. Med. 177, 376-387.
66. Li, X., Wu, K., Edman, M., Schenke-Layland, K., MacVeigh-Aloni, M., Janga, S.R., Schulz, B., and Hamm-Alvarez, S.F. (2010). Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands of male NOD mouse. Invest. Ophthalmol. Vis. Sci. 51, 5019-5029.
67. Libby, P. (2002). Inflammation and atherosclerosis. Circulation 105, 1135-1143.
68. Logar, D.B., Komadina, R., Prezelj, J., Ostanek, B., Trost, Z., and Marc, J. (2007). Expression of bone resorption genes in osteoarthritis and in osteoporosis. J. Bone Miner. Metab. 25, 219-225.
69. Lohoefer, F., Reeps, C., Lipp, C., Rudelius, M., Zimmermann, A., Ockert, S., Eckstein, H., and Pelisek, J. (2012). Histopathological analysis of cellular localization of cathepsins in abdominal aortic aneurysm wall. Int. J. Exp. Pathol. 93, 252-258.
70. Liu, J., Ma, L., Yang, J., Ren, A., Sun, Z., Yan, G., Sun, J., Fu, H., Xu, W., Hu, C., et al. (2006). Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 186, 411-419.
71. Lv, B-J., Lindholt, J.S., Cheng, X., Wang, J., and Shi, G-P. (2012). Plasma cathepsin S and cystatin C levels and risk of abdominal aortic aneurysm: a randomized population-based study. PLoS One 7, e41813.
72. Maciewicz, R.A. and Etherington, D.J. (1988). A comparison of four cathepsins (B, L, N and S) with collagenolytic activity from rabbit spleen. Biochem. J. 256, 433-440.
73. MacIntyre, A.C. and Cutler, D.J. (1988). The potential role of lysosomes in tissue distribution of weak bases. Biopharm. Drug. Dispos. 9, 513-526.
74. Mahmood, U., Tung, C.H., Bogdanov, A., and Weissleder, R. (1999). Near-infrared optical imaging of protease activity for tumor detection. Radiology 213, 866-870.
75. + hematopoietic stem cells of relapsingremitting multiple sclerosis patients. Mult. Scler. 19, 1443-1453.
76. McGrath, M.E., Palmer, J.T., Brömme, D., and Somoza, J.R. (1998). Crystal structure of human cathepsin S. Protein Sci. 7, 1294-1302.
77. Mikhaylov, G., Klimpel, D., Schaschke, N., Mikac, U., Vizovisek, M., Fonovic, M., Turk, V., Turk, B., and Vasiljeva, O. (2014). Selective targeting of tumor and stromal cells by a nanocarrier system displaying lipidated cathepsin B inhibitor. Angew. Chem. Int. Ed. Engl. 53, 10077-10081.
78. Mohamed, M.M. and Sloane, B.F. (2006). Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 6, 764-775.
79. Morton, P.A., Schwartz, B.D., Zacheis, L., Ciacoletto, K.S., and Manning, J.A. (1995). Nascent MHC class Il-invariant chain complexes to lysosomal compartments and proteolysis. J. Immunol. 154, 137-150.
80. Nakagawa, T.Y., Brissette, W.H., Lira, P.D., Griffiths, R.J., Petrushova, N., Stock, J., McNeish, J.D., Eastman, S.E., Howard, E.D., Clarke, S.R., et al. (1999). Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 10, 207-217.
81. Naour, N., Rouault, C., Fellahi, S., Lavoie, M., Poitou, C., Keophiphath, M., Eberle, D., Shoelson, S., Rizkalla, S., Bastard, J., et al. (2010). Cathepsins in human obesity: changes in energy balance predominantly affects cathepsin S in adipose tissue and in circulation. J. Clin. Endocrinol. Metab. 95, 1861-1868.
82. Naudin, C., Joulin-Giet, A., Couetdic, G., Plesiat, P., Szymanska, A., Gorna, E., Gauthier, F., Kasprzykowski, F., Lecaille, F., and Lalmanach, G. (2011). Human cysteine cathepsins are not reliable markers of infection by Pseudomonas aeruginosa in cystic fibrosis. PLoS One 6, e25577.
83. Nissler, K., Oerhing, H., Krieg, R., Pierskalla, A., Weber, E., Wiederanders, B., and Halbhuber, K.J. (2002). Cytochemical demonstration of expression and distribution of non-glycosylated human lysosomal cathepsin S in HEK 293 cells. Cell. Mol. Biol. 48, OL297-OL308.
84. Ochieng, J. and Chaudhuri, G. (2010). Cystatin superfamily. J. Health Care Poor. U. 21, 51-70.
85. Oresic Bender, K., Ofori, L., van der Lindin, W.A., Mock, E.D., Datta, G.K., Chowdhury, S., Li, H., Segal, E., Lopez, M.S., Ellman, J.A., et al. (2015). Design of a highly selective quenched activity-based probe and its application in dual colour imaging studies of cathepsin S activity localization. J. Am. Chem. Soc. 137, 4771-4777.
86. Otto, H. and Schirmeister, T. (1997). Cysteine proteases and their inhibitors. Chem. Rev. 97, 133-171.
87. Overall, C.M. and López-Otín, C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2, 657-672.
88. Papazafiropoulou, A. and Tentolouris, N. (2009). Matrix metalloproteinases and cardiovascular diseases. Hippokratia 13, 76-82.
89. Pauly, T.A., Sulea, T., Ammirati, M., Sivaraman, J., Danley, D.E., Griffor, M.C., Kamath, A.V., Wang, I-K., Laird, E.R., Seddon, A.P., et al. (2003). Specificity determinants of human cathepsin S revealed by crystal structures of complexes. Biochemistry 42, 3202-3213.
90. Payne, C.D., Deeg, M.A., Chan, M., Tan, L.H., La Bell, E.S., Shen, T., and De Brota, D.J. (2014). Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects. Br. J. Clin. Pharmacol. 78, 1334-1342.
91. Požgan, U., Caglic, D., Rozman, B., Nagase, H., Turk, V., and Turk, B. (2010). Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol. Chem. 391, 571-579.
92. Puente, X.S., Sánchez, L.M., Gutiérrez-Fernández, A., Velasco, G., and López-Otín, C. (2005). Proteases and their inhibitors in neurodegenerative disease a genomic view of the complexity of mammalian proteolytic systems. Biochem. Soc. Trans. 33, 331-334.
93. Qin, Y., Cao, X., Guo, J., Zhang, Y., Pan, L., Zhang, H., Li, H., Tang, C., Du, J., and Shi, G-P. (2012). Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Cardiovasc. Res. 96, 401-410.
94. Qin, Y., Yang, Y., Liu, R., Cao, X., Liu, O., and Liu, J. (2013). Combined Cathepsin S and hs-CRP predicting inflammation of abdominal aortic aneurysm. Clin. Biochem. 46, 1026-1029.
95. Rawlings, N.D., Barrett, A.J., and Bateman, A. (2012). MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 40, D343-350.
96. Reddy, V.B., Shimada, S.G., Sikand, P., Lamotte, R.H., and Lerner, E.A. (2010). Cathepsin S elicits itch and signals via proteaseactivated receptors. J. Invest. Dermatol. 130, 1458-1470.
97. Reiser, J., Adair, B., and Reinheckel, T. (2010). Science in medicine Specialized roles for cysteine cathepsins in health and disease. J. Clin. Invest. 120, 24-26.
98. 64Cu-labeled activity-based probe. PLoS One 6, e28029.
99. Repnik, U., Starr, A.E., Overall, C.M., and Turk, B. (2015). Cysteine cathepsins activate and inactivate non-ELR chemokines. J. Biol. Chem. 290, 13800-13811.
100. Riese, R.J., Wolf, P.R., Brömme, D., Natkin, L.R., Villadangos, J.A., Ploegh, H.L., and Chapman, H.A. (1996). Essential role for cathepsin S in MHC Class II-associated invariant chain processing and peptide loading. Immunity 4, 357-366.
101. Ruge, T., Sodergren, A., Wallberg-Jonsson, S., Larsson, A., and Arnlov, J. (2014). Circulating plasma levels of cathepsin S and L are not associated with disease severity in patients with rheumatoid arthritis. Scand. J. Rheumatol. 43, 371-373.
102. Rupanagudi, K.V., Kulkarni, O.P., Lichtnekert, J., Darisipudi, M.N., Mulay, S.R., Schott, B., Gruner, S., Haap, W., Hartmann, G., and Anders, H-J. (2015). Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann. Rheum. Dis. 74, 452-463.
103. Saftig, P., Hetman, M., Schmahl, W., Weber, K., Heine, L., Mossmann, H., Koster, A., Hess, B., Evers, M., Figura, K.V., et al. (1995). Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO. J. 14, 3599-3608.
104. Sasaki, T., Kuzuya, M., Nakamura, K., Cheng, X.W., Hayashi, T., Song, H., Hu, L., Okumura, K., Murohara, T., Iguchi, A., et al. (2010). AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice. Atherosclerosis 210, 430-437.
105. Schurigt, U. (2013). Role of cysteine cathepsins in joint inflammation and destruction in human rheumatoid arthritis and associated animal models. Inflamm. Res. 61, 1021-1029.
106. Schurigt, U., Stopfel, N., Hückel, M., Pfirschke, C., Wiederanders, B., and Bräuer, R. (2005). Local expression of matrix metalloproteinases, cathepsins, and their inhibitors during the development of murine antigen-induced arthritis. Arthritis Res. Ther. 7, R175-R188.
107. Sevenich, L., Bowman, R.L., Mason, S.D., Quail, D.F., Rapaport, F., Elie, B.T., Brogi, E., Brastianos, P.K., Hahn, W.C., Holsinger, L.J., et al. (2014). Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat. Cell Biol. 16, 876-888.
108. Shi, G-P., Webb, A.C., Foster, K.E., Knoll, J.H., Lemere, C.A., Munger, J.S., and Chapman, H.A. (1994). Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J. Biol. Chem. 269, 11530-11536.
109. Shi, G-P., Sukhova, G.K., Kuzuya, M., Ye, Q., Du, J., Zhang, Y., Pan, J-H., Lu, M.L., Cheng, X.W., Iguchi, A., et al. (2003). Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ. Res. 92, 493-500.
110. Small, D.M., Burden, R.E., and Scott, C.J. (2011). The emerging relevance of the cysteine protease cathepsin S in disease. Clin. Rev. Bone Miner. Metab. 9, 122-132.
111. Small, D.M., Burden, R.E., Jaworski, J., Hegarty, S.M., Spence, S., Burrows, J.F., McFarlane, C., Kissenpfennig, A., McCarthy, H.O., Johnston, J.A., et al. (2013). Cathepsin S from both tumour and tumour-associated cells promote cancer growth and neovascularisation. Int. J. Cancer 133, 2102-2112.
112. Storm van's Gravesande, K., Layne, M.D., Ye, Q., Le, L., Baron, R.M., Perrella, M.A., Santambrogio, L., Silverman, E.S., and Riese, R.J. (2002). IFN regulatory factor-1 regulates IFNgamma-dependent cathepsin S expression. J. Immunol. 168, 4488-4494.
113. Sukhova, G.K., Shi, G-P., Simon, D.I., Chapman, H.A., and Libby, P. (1998). Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest. 102, 576-583.
114. Sukhova, G.K., Zhang, Y., Pan, J., Wada, Y., Yamamoto, T., Naito, M., Kodama, T., Tsimikas, S., Witztum, J.L., Lu, M.L., et al. (2003). Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 111, 897-906.
115. Taggart, C.C., Lowe, G.J., Greene, C.M., Mulgrew, A.T., O'Neill, S.J., Levine, R.L., and McElvaney, N.G. (2001). Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J-Biol. Chem. 276, 33345-33352.
116. Taggart, C.C., Greene, C.M., Smith, S.G., Levine, R.L., McCray, P.B., O'Neill, S., and McElvaney, N.G. (2003). Inactivation of human defensins 2 and 3 by elastolytic cathepsins. J. Immunol. 171, 931-937.
117. Taglieri, N., Koenig, W., and Kaski, J.C. (2009). Cystatin C and cardiovascular risk. Clin. Chem. 55, 1932-1943.
118. Taleb, S., Lacasa, D., Bastard, J., Poitou, C., Cancello, R., Pelloux, V., Viguerie, N., Benis, A., Zucker, J., Bouillot, J., et al. (2005). Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis. FASEB J. 19, 1540-1542.
119. Taleb, S., Cancello, R., Clement, K., and Lacasa, D. (2006). Cathepsin S promotes human preadipocyte differenciation: possible involvement of fibronectin degradation. Endocrinology 147, 4950-4959.
120. Tan, A., Zhao, P., Waxman, S., and Hains, B. (2009). Early microglial inhibition preemptively mitigates chronic pain development after experimental spinal cord injury. J. Rehabil. Res. Dev. 46, 123-134.
121. Turk, B. (2006). Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug. Discov. 5, 785-799.
122. Turk, B., Turk, D., and Turk, V. (2000). Lysosomal cysteine proteases: more than scavengers. Biochim. Biophys. Acta. 1477, 98-111.
123. Turk, V., Kos, J., and Turk, B. (2004). Cysteine cathepsins (proteases)-On the main stage of cancer? Cancer. Cell. 5, 409-410.
124. Turk, B., Turk, D., and Turk, V. (2012a) Protease signalling: the cutting edge. EMBO. J. 31, 1630-1643.
125. Turk, V., Stoka, V., Vasiljeva, O., Renko, M., Sun, T., Turk, B., and Turk, D. (2012b). Cysteine cathepsins: From structure, function and regulation to new frontiers. Biochim. Biophys. Acta. 1824, 68-88.
126. Turnsek, T., Kregar, I., and Lebez, D. (1975). Acid sulphydryl protease from calf lymph nodes. Biochim. Biophys. Acta 403, 514-520.
127. Vázquez, R., Astorgues-Xerri, L., Bekradda, M., Gormley, J., Buick, R., Kerr, P., Cvitkovic, E., Raymond, E., D'Incalci, M., Frapolli, R., et al. (2014). Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors. Biochimie 108c, 101-107.
128. Veillard, F., Saidi, A., Burden, R.E., Scott, C.J., Gillet, L., Lecaille, F., and Lalmanach, G. (2011). Cysteine cathepsins S and L modulate anti-angiogenic activities of human endostatin. J. Biol. Chem. 286, 37158-37167.
129. Verdoes, M., Bender, K.O., Segal, E., van der Linden, W.A., Syed, S., Withana, N.P., Sanman, L.E., and Bogyo, M. (2013). Improved quenched fluorescent probe for imaging of cysteine cathepsin activity. J. Am. Chem. Soc. 135, 14726-14730.
130. Wang, B., Sun, J., Kitamoto, S., Yang, M., Grubb, A., Chapman, H.A., Kalluri, R., and Shi, G-P. (2006). Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J. Biol. Chem. 281, 6020-6029.
131. Watzke, A., Kosec, G., Kindermann, M., Jeske, V., Nestler, H., Turk, V., Turk, B., and Wendt, K.U. (2008). Selective activity-based probes for cysteine cathepsins. Angew. Chem. Int. Ed. Engl. 47, 406-409.
132. Weldon, S., McNally, P., McAuley, D.F., Oglesby, I.K., Wohlford-Lenane, C.L., Bartlett, J.A., Scott, C.J., McElvaney, N.G., Greene, C.M., McCray, P.B., et al. (2014). miR-31 Dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin s production. Am. J. Respir. Crit. Care Med. 190, 165-174.
133. Xin, X.Q., Gunesekera, B., and Mason, R.W. (1992). The specificity and elastinolytic activities of bovine cathepsins S and H. Arch. Biochem. Biophys. 299, 334-339.
134. Xu, J., Ke, Z., Maubach, G., and Zhuo, L. (2009). Cathepsin S is aberrantly overexpressed in human hepatocellular carcinoma. Mol. Med. Rep. 2, 713-718.
135. Xu, L., Feng, B., Wang, H., and Li, X. (2013). Multiple statistical methods for assessing differential gene expression in microarray data of diabetic model rats to predict the molecular mechanism of atorvastatin on anti-atherogenesis. Exp. Clin. Endocrinol. Diabetes 121, 272-279.
136. Zerbini, C.A.F. and McClung, M.R. (2013). Odanacatib in postmenopausal women with low bone mineral density: a review of clinical evidence. Ther. Adv. Musculoskel. Dis. 5, 199-209.
137. Zhao, P., Lieu, T., Barlow, N., Metcalf, M., Veldhuis, N., Jensen, D., Kocan, M., Sostegni, S., Haerteis, S., Baraznenok, V., et al. (2014). Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4. J. Biol. Chem. 289, 27215-27234.
138. Zhuo, M., Wu, G., and Wu, L.J. (2011). Neuronal and microglial mechanisms of neuropathic pain. Mol. Brain 4, doi: 10.1186/1756-6606-4-31.